BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       
BioNews - BioPortfolio's News Portal
Biotechnology Regulatory Headlines

Sign-up to BioPortfolio's
Biotechnology Regulatory FDA news alerts.
Subscribe to BioWatch News Email alerts - open BioWatch PDF brochure.
Publish your news using BioNewsCast - open BioNewsCast PDF brochure.

Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisatio
Press Trust of India:  similar ...
From the Editor: The Right Stuff
Pharmaceutical Manufacturing Magazine:  similar ...
Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalizat
DiGiTAL50:  similar ...
Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hosp
Antara Interactive:  similar ...
NeurogesX to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
KOTA Territory News:  similar ...
Biophage Pharma announces sale of Immunotox Labs Division to Validapro BioSciences Inc
Yahoo! Canada:  similar ...
NeurogesX Reports First Quarter 2008 Results
KOTA Territory News:  similar ...
Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisatio
Canadian Business Magazine:  similar ...
COMMUNIQUE: PR Newswire: BELG Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in
Belga Direct Press Releases:  similar ...
Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisatio
Bolsamania:  similar ...
Landmark ATHENA Study Findings With Multaq (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization
Pharma Live:  similar ...
Landmark ATHENA Study Findings With Multaq(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisation
Financial Post:  similar ...
Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisatio
TradingMarkets:  similar ...
Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalizat
Macro World Investor:  similar ...
Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisatio
Canada NewsWire:  similar ...
Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisatio
Yahoo! Canada:  similar ...
Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisatio
Market Wire:  similar ...
Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalizat
PR Newswire:  similar ...
Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows
PR Newswire via MSN Money:  similar ...
Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalizat
Stockwatch:  similar ...

Search BioNews

      ---Advanced searching---

Sign-up to BioPortfolio's Biotechnology Regulatory FDA news alerts.
Subscribe to BioWatch News Email alerts - open BioWatch PDF brochure.
Publish your news using BioNewsCast - open BioNewsCast PDF brochure.

 

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.